{"id":"NCT00916370","sponsor":"Abbott Medical Devices","briefTitle":"SPIRIT PRIME Clinical Trial","officialTitle":"SPIRIT PRIME Clinical Trial.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-03","completion":"2014-02","firstPosted":"2009-06-09","resultsPosted":"2012-06-01","lastUpdate":"2015-06-08"},"enrollment":525,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myocardial Ischemia","Coronary Artery Stenosis","Coronary Disease","Coronary Artery Disease","Coronary Restenosis"],"interventions":[{"type":"DEVICE","name":"Core size Xience Prime","otherNames":[]},{"type":"DEVICE","name":"Xience Prime Long Lesion (LL)","otherNames":[]}],"arms":[{"label":"Core size registry (CSR)","type":"EXPERIMENTAL"},{"label":"Long lesion registry (LLR)","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.","primaryOutcome":{"measure":"Target Lesion Failure (TLF)","timeFrame":"1 year","effectByArm":[{"arm":"Core Size Registry","deltaMin":4.5,"sd":null},{"arm":"Long Lesion Registry","deltaMin":7.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":203,"n":412},"commonTop":["Angina pectoris","Non-cardiac chest pain","Back pain","Headache","Dyspnoea"]}}